Synapse - Works

Results (5608)

Final results of a multicenter prospective phase II clinical trial of gemcitabine and cisplatin as neoadjuvant chemotherapy in patients with high-grade upper tract urothelial carcinoma

Meeting Abstract

Yip, W.; Coleman, J.; Wong, N. C.; Sjoberg, D. D.; Bochner, B. H.; Dalbagni, G.; Donat, S. M.; Herr, H. W.; Pietzak, E. J.; Hakimi, A. A.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Defining hereditary upper tract urothelial carcinoma: Implications for genetic testing and clinical management

Meeting Abstract

Truong, H.; Sheikh, R.; Kemel, Y.; De Jesus Escano, M.; Khurram, A.; Reisz, P.; Lenis, A. T.; Goh, A. C.; Cha, E. K.; Bochner, B. H.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Phase 1 study of P-PSMA-101 CAR-T cells in patients with metastatic castration-resistant prostate cancer (mCRPC)

Meeting Abstract

Slovin, S. F.; Dorff, T. B.; Falchook, G. S.; Wei, X. X.; Gao, X.; McKay, R. R.; Oh, D. Y.; Wibmer, A. G.; Spear, M. A.; McCaigue, J.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

PSMAfore: A phase 3 study to compare (177)Lu-PSMA-617 treatment with a change in androgen receptor pathway inhibitor in taxane-naïve patients with metastatic castration-resistant prostate cancer

Meeting Abstract

Sartor, A. O.; Morris, M. J.; Chi, K. N.; De Bono, J. S.; Shore, N. D.; Crosby, M.; Kreisl, T. N.; Fizazi, K.
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Real-world assessment of changing treatment patterns and sequence for patients with metastatic renal cell carcinoma (mRCC) in the first-line (1L) setting

Meeting Abstract

Shah, N. J.; Sura, S.; Shinde, R.; Shi, J.; Perini, R. F.; Puneet, S.; Robert, N. J.; Vogelzang, N. J.; Motzer, R. J.
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Real-world clinical outcomes of patients (pts) with metastatic renal cell carcinoma (mRCC) in current immune-oncology (IO) and tyrosine kinase inhibitors (TKIs) era

Meeting Abstract

Shah, N. J.; Sura, S.; Shinde, R.; Shi, J. X.; Perini, R. F.; Puneet, S.; Robert, N. J.; Vogelzang, N. J.; Motzer, R. J.
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Efficacy and safety of nivolumab plus ipilimumab (N+I) versus sunitinib (S) for first-line treatment of patients with advanced sarcomatoid renal cell carcinoma (sRCC) in the phase 3 CheckMate 214 trial with extended 5-year minimum follow-up

Meeting Abstract

Tannir, N. M.; Signoretti, S.; Choueiri, T. K.; McDermott, D. F.; Motzer, R. J.; George, S.; Powles, T.; Donskov, F.; Tykodi, S. S.; Pal, S. K.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Clinical pharmacology of the antibody-drug conjugate enfortumab vedotin in advanced urothelial carcinoma and other malignant solid tumors

Meeting Abstract

Tang, M.; Garg, A.; Bonate, P.; Rosenberg, J. E.; Kadokura, T.; Yamada, A.; Fukushi, R.; Koibuchi, A.; Hanley, W. D.; Poondru, S.
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

First look at patient reported outcomes from IRONMAN, the international registry of men with advanced prostate cancer

Meeting Abstract

Rencsok, E.; George, D. J.; Kantoff, P. W.; Villanti, P.; Vinson, J.; Gerke, T. A.; Hyslop, T.; Mucci, L. A.
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Post hoc pooled analysis of first-line (1L) pembrolizumab (pembro) for advanced urothelial carcinoma (UC): Outcomes by response at week nine in KEYNOTE-052 and KEYNOTE-361

Meeting Abstract

Powles, T.; Alva, A. S.; Ozguroglu, M.; O'Donnell, P. H.; Loriot, Y.; Csoszi, T.; Vuky, J.; Morales-Barrera, R.; Plimack, E. R.; Matsubara, N.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save